… malaria vaccine developed by GlaxoSmithKline (GSK), has been found to provide 35%–53%
protection against P. falciparum malaria … malaria vaccine candidate in Tanzanian children …

… Tanzania, where a malaria vaccine clinical trial was conducted. Analyzing the impacts of the
malaria vaccine … Those most vulnerable to malaria are children under the age of five, who …

… The Spf66 vaccine construct was able to induce higher antibody titers and … a malaria
vaccine, ten Tanzanian adults and 40 children aged between 5 and 9 years old living in a malaria-…

… of 1,040 children under five years of age, with fever, were screened for malaria parasites
during the study period. Five hundred and seventy six (55.4%) were found positive for malaria …

… SPf66 provided the scientific community focusing on malaria … in humans (adults and children
aged more than 1 year old) … expanded programme of immunisation in Tanzania, as was …

… on the brain vasculature of 31 children who died from human cerebral malaria. A substantial
number of … The vaccination of multistage antigen SpF66 combined with alum resulted in the …

… of the effects of SPf66 malaria vaccine in African children exposed to intense transmission of
… of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. …

… observations suggest that a malaria vaccine may be achievable. … from malaria in endemic
areas occur in children under 5 … in humans is the Spf66 synthetic peptide vaccine devised by …

… vaccine-induced protection from malaria infection and disease was demonstrated in African
children… blood-stage malaria vaccine to be developed was the SPf66 vaccine candidate that …

… 832 infants born at one hospital in a malaria-hyperendemic area of Tanzania between …
of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. …